The door to the trillion-dollar market that you don’t know is being opened by AI.
"When it comes to artificial intelligence, it was easy for people to think of autonomous driving and assisted diagnosis in the past, but biological computing will become the real main battlefield in the future" - Dean of of Beijing Big Data Research Institute and academician of the Chinese Academy of Sciences E Weinan
Since last year, news about AI in the field of pharmaceutical has been continuously reported, and many emerging AI pharmaceutical companies have been emerging, and more early layout companies have continued to refresh financing records, and a series of actual results have been implemented one after another. Coincidence or inevitable?
For the industry, the pharmaceutical industry has accumulated problems for many years, and the cost of new drug research and development remains high.
For technology, the pharmaceutical industry spans several disciplines and is extremely difficult, so it is particularly difficult to tell a good story about AI;
However, under the dual promotion of technology and entrepreneurs, the potential of AI is gradually being revealed from identifying biological targets, compound screening, compound synthesis, to providing personalized treatments and predicting clinical trial results.
Perhaps now is the most special stage in the AI pharmaceutical industry. The emergence of these pioneer AI companies such as small molecule drugs, cutting-edge omics and detection has made the doors of many 100 billion tracks open.
At the same time, this rising craze also provides new opportunities to pursue dreams for countless entrepreneurs who dare to choose.
From May 17 to 28, Leifeng.com invited the founders and R&D leaders of Baitu Shengke , Wangshi Wisdom, Unknown Jun, Litai Biological, Xingyao Technology, Yingsi Intelligence and other companies to deconstruct the technical logic of this trend for everyone in the form of a cloud summit and the different strategies of each company, bringing readers a sharing of dry goods that combines "industry education" and "demand cooperation".
Guest agenda introduction
Gao Xin
Baitu Biotechnology Science Consultant,
Professor of King Abdullah University of Science and Technology,
Speech Topic: More accurate Biomedical and genomics
Guest introduction: Currently, he is a professor and doctoral supervisor of the Department of Computer Science, King Abdullah University of Science and Technology (KAUST), Saudi Arabia, and serves as deputy director of the KAUST Research Center for Computational Biology, deputy director of the KAUST Smart Medical Center, and head of the KAUST Structural and Functional Bioinformatics Research Group.
Professor Gao Xin's research focus is mainly on the intersection of computer science and biology. In the field of computer science, the research team he leads is mainly dedicated to developing machine learning theories and methods related to deep learning, probability graph models, kernel methods, and matrix decomposition.
In the field of bioinformatics, his research team is mainly committed to building computing models, developing machine learning technologies, and designing efficient algorithms to solve the problems from biological sequence analysis to three-dimensional structure determination, to functional annotation, and then to understanding and controlling molecular behavior in complex biological networks.
Lai Caida
dosesTaiwan Pharmaceutical CEO
Speech title: AI drives the development of new drug preparations
Speech outline:
Artificial intelligence drives the development of new drug preparationsDiscovery status
Artificial intelligence-high-throughput experiments collection R&D platform and case sharing
505(b)(2)New drug development strategies and case sharing
Guest profile: Mits Institute of Technology (MIT) PhD, developing process optimization and QbD digital process design at Novartis Research Center. During his PhD, he founded AquaFresco, a new water purification technology creation, and won many new awards including MassChallenge.
Dr. Lai is a serial entrepreneur specializing in drug manufacturing processes and new drug digitalization strategies. He has worked as a strategic consultant at McKinsey, assisting the digital strategy and market development of Fortune 500 pharmaceutical companies, and planning and organizing restructuring and other businesses. He founded METiS Hangzhou Litai Pharmaceutical in 2019 and served as CEO.
Tan Zhuang
Unknown Jun CEO
Speech title: Clinical research on intestinal microecology drugs empowered by AI
Guest introduction: has a doctorate degree in biological information and computational biology and a bachelor's degree in biotechnology from Peking University. He has completed his doctoral research at the Broad Institute of Massachusetts Institute of Technology in the United States, with fields ranging from bioinformatics, microbiology and immunology.
In 2017, Tan Zheng founded Weizhijun Biotechnology; in 2018, he was rated as a Peacock Talent in Shenzhen; in 2019, he was hired as the tutor of the " Institute of Microbiology, Chinese Academy of Sciences" master's degree in biological engineering, and chairman of the "Joint Laboratory of Microecology Pharmaceuticals, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences"; in 2020, he was rated as "35 people under 35 science and technology innovation" by the "Mits Science and Technology Review".
Zhou Wenbiao
Wangshi Intelligence Advanced Algorithm Expert
Speech Topic: Application and Challenge of AI+ Drug Development
Speech Outline:
AI Accelerate Drug Research and Development Practical Ideas and Paths
AI Based on AI Drug Molecular Discovery and Screening Process
AI
The roles of different AI modules
The new drug application case of mainstream AI algorithms
Guest introduction: graduated from Beijing Institute of Technology computer major, and has been engaged in algorithm work in Baidu and Qunar.com for the past ten years. He has rich experience in in-depth research and successful implementation of AI in intelligent customer service, large-scale image search and personalized recommendation systems. Currently, he serves as a senior algorithm expert in Wangshi Intelligence and is in charge of the molecular design algorithm team, involving molecular generation, molecular screening, drug properties prediction and other aspects.
Ren Feng
Eng Silicon Intelligence Chief Scientific Officer, Head of Drug R&D
Speech Title: Artificial Intelligence Accelerates New Drug R&D
Guest Profile: Graduated from Hardware University in 2007 from the Department of Chemistry of Harvard University in the United States, with more than ten years of experience in small molecule innovative drugs R&D by multinational pharmaceutical companies (GlaxoSmithKline ). He has served as chief researcher, deputy director, director, and head of the Chemistry Department. Successfully developed several clinical candidate compounds/clinical compounds for the treatment of Parkinson's disease, , multiple sclerosis, pain, and psoriasis.
joined Shanghai Medixi in 2018 and served as vice president and senior vice president. He is fully responsible for the R&D service business of the Department of Chemistry and Biology and the company's drug discovery platform service business. In 2019, the company successfully listed on " Science and Technology Innovation Board ".
2021, joined Insilico Medicine as Chief Scientific Officer, responsible for using the company's artificial intelligence platform to build preclinical/clinical product pipelines and external project cooperation. Dr. Ren Feng has published more than 30 international academic papers and more than 20 international patents.
Li Chengtao
Founder and CEO of Star Pharmaceutical Technology, founder and CEO of Star Pharmaceutical Technology, Lecture Title: Application of Artificial Intelligence in the Research and Development of Small Molecular Drugs
Guest Profile: graduated from the Yao class of Tsinghua University, and holds a doctorate in computer science from MIT. With years of research experience in machine learning and artificial intelligence, he is the proposer of multiple innovative models, and has published more than a dozen papers in top artificial intelligence conferences and scientific journals. He is one of the top scholars in the field of artificial intelligence + drug research and development.
Dr. Li founded Star Pharmaceutical Technology in 2019 and served as CEO, focusing on various applications of artificial intelligence in the field of drug research and development; at the same time, he is also one of the initiators of the origin of the same and different origins of the interdisciplinary knowledge sharing platform. How to participate in the meeting
? Reply to the keyword "participate in the meeting" on the
dialog box, you can enter the WeChat group to watch the live broadcast, or chat and laugh with entrepreneurs.
courses are for the crowd
Artificial intelligence and medical technology companies executives, researchers
University computers, artificial intelligence professors and graduate students
Head of science and research and development department of pharmaceutical companies
People who are very interested in the application of artificial intelligence in the medical field
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-